Altimmune (ALT) Other Non-Current Liabilities (2010 - 2026)
Altimmune (ALT) posted quarterly Other Non-Current Liabilities of $5.8 million for Q1 2026, up 36243.75% year-over-year from N/an in Q1 2025, and up 1.08% quarter-over-quarter from $5.8 million in Q4 2025.
Altimmune (ALT) Other Non-Current Liabilities (2010 - 2026) Analysis & Trends
Altimmune (ALT) has reported Other Non-Current Liabilities for 17 consecutive years, with $5.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 36243.75% year-over-year to $5.8 million; the TTM figure through Mar 2026 stood at $5.8 million (up 36243.75% YoY), while the FY2025 annual figure was $5.8 million, up 7.94% from the prior year.
- Other Non-Current Liabilities rose to $5.8 million in Q1 2026 per ALT's latest filing, from $5.8 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $5.8 million in Q1 2026 and bottomed at $16000.0 in Q1 2025.
- Historically, Other Non-Current Liabilities has averaged $2.7 million across 5 years, with a median of $2.2 million in 2022.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities slumped 99.01% — and 2026, when it surged 36243.75%.
- Altimmune's Other Non-Current Liabilities stood at $60000.0 in 2022, then plunged by 33.33% to $40000.0 in 2023, then jumped by 13225.0% to $5.3 million in 2024, then gained by 7.94% to $5.8 million in 2025, then grew by 1.08% to $5.8 million in 2026.
- Business Quant data shows ALT's Other Non-Current Liabilities at $5.8 million in Q1 2026, $5.8 million in Q4 2025, and $5.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Altimmune | 571.75 Mn | 571.75 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.76 Mn |
| Mar 31, 2026 | 5.82 Mn |
| Dec 31, 2025 | 5.75 Mn |
| Sep 30, 2025 | 5.80 Mn |
| Jun 30, 2025 | 5.43 Mn |
| Mar 31, 2025 | 16,000.00 |
| Dec 31, 2024 | 5.33 Mn |
| Sep 30, 2024 | 26,000.00 |
| Jun 30, 2024 | 31,000.00 |
| Mar 31, 2024 | 37,000.00 |
| Dec 31, 2023 | 40,000.00 |
| Dec 31, 2022 | 60,000.00 |
| Mar 31, 2022 | 4.31 Mn |
| Dec 31, 2021 | 6.09 Mn |
| Sep 30, 2021 | 6.95 Mn |
| Jun 30, 2021 | 5.27 Mn |
| Mar 31, 2021 | 6.27 Mn |
| Dec 31, 2020 | 5.39 Mn |
| Sep 30, 2020 | 25.07 Mn |
| Jun 30, 2020 | 16.39 Mn |